Innoviva, Inc. (INVA): Price and Financial Metrics

Innoviva, Inc. (INVA): $16.51

0.27 (+1.66%)

POWR Rating

Component Grades













Add INVA to Watchlist
Sign Up

Industry: Biotech


of 505

in industry


  • INVA scores best on the Value dimension, with a Value rank ahead of 94.46% of US stocks.
  • INVA's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • INVA's current lowest rank is in the Momentum metric (where it is better than 11.35% of US stocks).

INVA Stock Summary

  • INVA's current price/earnings ratio is 4.26, which is higher than just 4.17% of US stocks with positive earnings.
  • The ratio of debt to operating expenses for Innoviva Inc is higher than it is for about 96.39% of US stocks.
  • Innoviva Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 34.92%, greater than the shareholder yield of 93.07% of stocks in our set.
  • Stocks that are quantitatively similar to INVA, based on their financial statements, market capitalization, and price volatility, are TRN, HTGC, NOVA, CSV, and SPR.
  • Visit INVA's SEC page to see the company's official filings. To visit the company's web site, go to

INVA Valuation Summary

  • INVA's price/earnings ratio is 4; this is 89.04% lower than that of the median Healthcare stock.
  • Over the past 206 months, INVA's price/sales ratio has gone down 124.5.
  • Over the past 206 months, INVA's EV/EBIT ratio has gone up 11.2.

Below are key valuation metrics over time for INVA.

Stock Date P/S P/B P/E EV/EBIT
INVA 2021-08-31 2.9 3.2 4.0 4.0
INVA 2021-08-30 2.9 3.2 4.0 4.0
INVA 2021-08-27 2.8 3.1 3.8 3.9
INVA 2021-08-26 2.8 3.1 3.8 3.8
INVA 2021-08-25 2.8 3.1 3.9 3.9
INVA 2021-08-24 3.0 3.3 4.1 4.1

INVA Growth Metrics

  • Its 4 year cash and equivalents growth rate is now at 131.91%.
  • The 2 year price growth rate now stands at -3.17%.
  • The 3 year revenue growth rate now stands at 270.36%.
INVA's revenue has moved up $104,478,000 over the prior 18 months.

The table below shows INVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 365.494 328.559 265.192
2021-03-31 343.634 323.739 253.088
2020-12-31 336.794 313.113 224.402
2020-09-30 322.289 294.738 216.448
2020-06-30 299.35 277.582 228.039
2020-03-31 284.511 254.284 188.935

INVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INVA has a Quality Grade of B, ranking ahead of 76.94% of graded US stocks.
  • INVA's asset turnover comes in at 0.385 -- ranking 121st of 677 Pharmaceutical Products stocks.
  • AERI, ACOR, and CALA are the stocks whose asset turnover ratios are most correlated with INVA.

The table below shows INVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.385 1 0.331
2021-03-31 0.353 1 0.337
2020-12-31 0.375 1 0.336
2020-09-30 0.389 1 0.354
2020-06-30 0.390 1 0.363
2020-03-31 0.402 1 0.302

INVA Price Target

For more insight on analysts targets of INVA, see our INVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 2.5 (Moderate Sell)

INVA Stock Price Chart Interactive Chart >

Price chart for INVA

INVA Price/Volume Stats

Current price $16.51 52-week high $16.72
Prev. close $16.24 52-week low $9.21
Day low $16.12 Volume 606,800
Day high $16.56 Avg. volume 653,791
50-day MA $14.97 Dividend yield N/A
200-day MA $12.96 Market Cap 1.15B

Innoviva, Inc. (INVA) Company Bio

Innoviva is a biopharmaceutical company. The Company develops small molecule medicines for respiratory disease, bacterial infections, and gastrointestinal disorders. The company was founded in 1996 and is based in South San Francisco, California.

INVA Latest News Stream

Event/Time News Detail
Loading, please wait...

INVA Latest Social Stream

Loading social stream, please wait...

View Full INVA Social Stream

Latest INVA News From Around the Web

Below are the latest news stories about Innoviva Inc that investors may wish to consider to help them evaluate INVA as an investment opportunity.

Innoviva Reports Second Quarter 2021 Financial Results

BURLINGAME, Calif., July 28, 2021--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" and "the Company") today reported financial results for the second quarter ended June 30, 2021.

Yahoo | July 28, 2021

Have Insiders Been Buying Innoviva, Inc. (NASDAQ:INVA) Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

Yahoo | July 16, 2021

Are Institutions Heavily Invested In Innoviva, Inc.'s (NASDAQ:INVA) Shares?

A look at the shareholders of Innoviva, Inc. ( NASDAQ:INVA ) can tell us which group is most powerful. Large companies...

Yahoo | June 10, 2021

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that, following a vote in favor of the transaction by the Armata shareholders, the Company has completed the closing of the second and final tranche of the Company's $20 million private placement of its common stock with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (NASDAQ: INVA) (together, "Innoviva"). In connection with the second closing, Armata issued 4,285,935 common shares and 4,285,935 warrants with an exercise price of $3.25 per share, at a per unit price of $3.25 per unit, in exchange for gross proce...

Yahoo | March 17, 2021

Moving Average Crossover Alert: Innoviva

Innoviva (INVA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Yahoo | March 8, 2021

Read More 'INVA' Stories Here

INVA Price Returns

1-mo 5.56%
3-mo 22.66%
6-mo 38.62%
1-year 47.61%
3-year 10.43%
5-year 44.07%
YTD 33.25%
2020 -12.50%
2019 -18.85%
2018 22.97%
2017 32.62%
2016 1.52%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8607 seconds.